SCHEMBL3534416

SCHEMBL3534416

Cc1nc2cc(-c3cnc(N)c4c(-c5ccc(N)cc5)csc34)ccc2s1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.63
AURKB Q96GD4 7/20 0.63
BTK Q06187 5/20 0.63
MAP4K4 O95819 4/20 0.63
ABL1 P00519 4/20 0.63
FYN P06241 4/20 0.63
CSF1R P07333 4/20 0.63
LYN P07948 4/20 0.63
FGFR1 P11362 4/20 0.63
FLT1 P17948 4/20 0.63
FLT4 P35916 4/20 0.63
BLK P51451 4/20 0.63
LIMK1 P53667 4/20 0.63
MAP4K2 Q12851 4/20 0.63
MINK1 Q8N4C8 4/20 0.63
PRKD2 Q9BZL6 4/20 0.63
SLK Q9H2G2 4/20 0.63
FGFR3 P22607 3/20 0.63
CLK4 Q9HAZ1 3/20 0.63
MAP4K5 Q9Y4K4 3/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534379 1.00 KDR (0.63) KDRAURKBBTKMAP4K4ABL1
SCHEMBL3530331 0.85 KDR (0.59) KDRAURKBBTKMAP4K4ABL1
SCHEMBL3529022 0.85 KDR (0.64) KDRAURKBBTKMAP4K4ABL1
SCHEMBL4489673 0.85 EPHB4 (0.68) KDRAURKBBTKMAP4K4ABL1
SCHEMBL3528912 0.81 BTK (0.61) KDRAURKBBTKMAP4K4ABL1
SCHEMBL3532445 0.79 KDR (0.68) KDRAURKBBTKMAP4K4ABL1
SCHEMBL3531566 0.79 KDR (0.75) KDRAURKBBTKMAP4K4ABL1
SCHEMBL3526606 0.78 FGFR1 (0.67) KDRAURKBBTKMAP4K4ABL1
SCHEMBL3560674 0.78 LCK (1.00) KDRAURKBBTKMAP4K4ABL1
SCHEMBL3560670 0.78 LCK (1.00) KDRAURKBBTKMAP4K4ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885BTK 103/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885BTK 103/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885BTK 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.